to and call fiscal Thank earnings of quarter everyone, for XXXX. third you, year operator our the welcome,
performance. the remainder discuss in third Let XXXX plan started with a a drivers my of our the we operational open then With and the results and let's overview Tim to I'll progress of discussion recent questions. of with and outlook cover year. our that, a performance me revenue earnings fiscal what updated review begin financial a our followed get by guidance call. overview our performance, with today. fiscal review our on we brief in We'll then will revenue remarks detail which of quarter today's our begin our release the press for of quick quarterly of call thoughts on key our for
a representing $XX.X reported we total growth third of the In XXXX, fiscal of on XXX% basis. of million, year-over-year quarter revenue
year-over-year, Device increased Diagnostics or by a performance growth exceptionally revenue in in IVD revenue XXX% our was in-Vitro segment Medical than strong segment. our decrease XX% Our offsetting from driven which more total
FDA and device for growth drug-coated of premarket Our benefited from achievement total revenue balloon. revenue approval SurVeil the medical our
during I'll this underlying payment in on I'm received our delivered quarter partner, $XX during the further million revenue. later achievement, in well. Abbott, basis pleased commercial milestone accomplishment million $XX.X a of of report as discuss an a of we important this the performance remarks. to strong as which we that quarter result my As detail from recognized was
milestone, PMA growth the revenue Medical driven the we achieved Excluding XX% growth year-over-year, revenue segment of XX% total Device year-over-year. by of total
business, segment of impressive pounds Device sales was product our across primarily coating portfolio, and strength including largely fueled of segment with sales product by our The sales This Medical sales. in our increased our XX% supplying along performance driven our product Device performance year-over-year, Medical by products, reagents. primarily In as in manage elevated our sales pleased all, third revenue were decreased softness customers lines the we inventory the quarter. driven the several product quarter. across taking IVD steps saw year-over-year our we performance our with during core in All to was levels by
an recent our to operational highlights. on update Shifting
by IVD offerings discussing Abbott, FDA During pipeline Sublime drive to strategic quarter, advance to the to progress PMA to commercialization. balloon intervention each radial of I'll important to the to these our of progress commercialization for key then Two, SurVeil respect continuing platforms; recent performance our and vascular commercialize three, for products one, objectives which start of and and revenue support prepare our flow cash from are: and our thrombectomy with fiscal advance as partner, while or approval medical arterial coatings the and third premarket our to product. Pounce each drug-coated our made a businesses. they device the initial growth as of XXXX, our X towards achieve reminder team objectives with respect
feedback on the from securing third the Beginning with and secured with the formal quarter fiscal 'XX DCB. the required the in team application strong front, our objective, amend process to PMA entered successfully We review the content additional the our FDA's for first that momentum provided strategic having PMA. SurVeil clarity for regulatory
obtained As additional we quarter XXXX. us in shared be the amended enable application secure quarter prepare to and of the by a an submission PMA press PMA release would XX, for we on to fourth in the March clarity third the fiscal believe
clarify X transluminal may our We with and submitted review approval, With our physicians process. to application and femoral de for in submission, of On our sold marketed FDA's percutaneous to restenotic X team millimeters. preparation, In than lesions vessel to less FDA premarket stated and following to were of to in facilitate for FDA aspects length or and XX, balloon. the the popliteal this angioplasty SurVeil novo to now review of receipt this continue equal XXX after up the approval leading or DCB diameters drug-coated announce the our to in vessel May, expectations. submission discuss proud having engage team PMA the millimeters to consistent with appropriate be reference months our and U.S. June in we their SurVeil of to lotteries,
one in culmination peripheral the Securing coating history It applying us of expertise to enable organization. achievements patients that the SurVeil option technologies. a will next-generation physicians developing our with provide represents significant the treatment drug-eluting organization of artery an an the of most and as leverages decades PMA for disease, for and of as XX-year in one our
and SurVeil XXX and reducing patient strong results drug the capabilities leverages The of trial. clinical drug of This our with SurVeil to of approval efficient that DCB efficacy also transfer proprietary and distribution, TRANSCEND DCB downstream while further promotes profile our the uniform region more a emboli. and represents target particulates the our more design safety technologies validation
and market-leading trial are safety this having the SurVeil DCB device DCB. are with of outcomes results clinical competitive paclitaxel results achieves X-year demonstrated, to the the despite XX% the These As compared the more that consistent SurVeil device.
concerns represents peripheral disease has whether in of challenges and navigated in XXXX, working the of development, it FDA questions. order numerous our by in paclitaxel product the to partnership use their including heightened Given agency hard of had teams with clinical accomplishment approval, the made to beginning this their artery a through for also possible secure the that commitment be regulatory and to to treatment work, satisfy years of herculean dedication
With focused commercial been team on supporting the now they has our PMA Abbott, squarely for our commercialization. in as partner, hand, prepare U.S.
SurVeil's been and with the team for operations We've engaged Abbott's actively plan launch. commercial to refine commercial
product our initial fiscal XXXX, with to the in at SurVeil anticipated fourth in of see commercialization, stocking As are look this the are time commercialize expect a future with and in terms publicly we quarter of for we during the responsible sharing receive the we respect reminder, terms order with XXXX. DCB, they can earnings Abbott while supplying to limited under we what manufacturing We of as commercialization details fiscal the call. more to Abbott's forward agreement,
focused to satisfy all year, DCB to Since focused pre-commercial readiness runs and a commercial retain of raw receiving production launch. experienced for order team the processes. manufacturing positioned members the have materials, continued the successful activities initial support throughout initial our has standpoint, ensure PMA, well test up our subsequent to on quality From the with as started on we SurVeil this engine been stocking well as Abbott's we our team to orders. We've With people to are manufacturing the production. SurVeil respect
hired needs satisfy thousands SurVeil the are place clinical and scale. in the the members meet to additional also support building to we future for units as we capacity, short, responsible to been of recent needs. years have In positioned processes of with in We've and regulatory commercial team partners. several provide who well materials our Teams
the risk care, leverages excited enhance and Given that next-generation peripheral drug Abbott's look the solution our agency's this presented to their medical providers a and infrastructure, and our summarize portfolio pivotal to care we believe best-in-class by innovative partnership. patients collaboration we a we're forward our paclitaxel-coated and expertise complement to the On be latest coated existing will on challenges that see address use product We entering July potential and vascular letter distribution physicians provide their continued to as effective health with published commercial the we safe, were market or to note, Abbott of technology disease. stage in related balloon excited of devices. XX artery presence our with FDA to a
conclusion peripheral earlier to is FDA health letter artery been scrutiny of past an area risk an paclitaxel-coated that applies focus on on devices. totality the the to on available supported I posted and has increased devices not devices. to a providers and of data FDA follow-up my analysis mentioned does to risk It July goes for regulatory to all XX, has a in mortality. conclusion concerns. the care published remarks, excess reached disease [indiscernible] agency the the XXXX, analyses that the this mortality The clarify paclitaxel titled paclitaxel-coated increase that that treat and in X states As of for decision their It January support years unlikely since paclitaxel-coated sharing letter
were that We the product to based leveling on FDA data. with state will and to current lever pleased the update they the see also device manufacturers work available
in this we XXXX. the warning look leading SurVeil other and work terms were update that working to labeling forward does agency to include to initially the by with to standard product In with with related labeling to believe the to letter the in to process. fairly in a raised The provides We will devices noted this the straightforward of based make July for paclitaxel. they the DCB implications, closure respect needed expect the letter DCB data. Like FDA currently its that SurVeil on our important device market, product updates be a current manufacturers agency the concerns
and Moving of strategic the Pounce commercialization radial platforms. initial arterial objective, advancing to our second thrombectomy our supplying
an achieved we Pounce as From pleased product our navigate work the potential of with at team earlier, that a sales commercial the direct to physicians sales products growth value are analysis device with and in the business of important they standpoint, our supplying products committees. I to through accounts sales execution As we were mentioned contributor XX% third new medical our quarter.
the result continue more target Pounce stated we XXX the achieved customers fiscal for than customers progress XXXX to at of of our in make our our expanding XXX As quarter for of to with and supplying efforts, we a over of platforms and their second base expectations. our compared quarter ending the ahead third end
pleased reduction the implemented over with entered we quarter. just we the made considering during the strong X Given with we're customers, over that first the XXXX the especially fiscal XXX second year, months progress that of fiscal workforce
progress customers conversions the in and reordering sales new Our in we despite we're the make of considering remaining products number in value customer growth quarter line committees well. pipeline our continued seeing March of with users as prospective from with pleased to the expanding team our a remain analysis with existing
progress stability continued with see terms the with tenure market we a respect Thrombectomy In the to at compared education during Pounce of will in our beginning size therapeutic compelling continue we're of of quarter we our team, QX. study managers an at end further make From System third this standpoint, of the as which the with territory real-world believe PROWL territory third quarter. benefits to the XX underscore average We of months quarter to during pleased used XX managers XX initiated study to Arterial settings. registry our
part We educate interim raise sites end efforts data customers at awareness. to continue as and and sharing market are the with at of patients enrolling current to we X and quarter prospective anticipate our
from in fiscal the first squarely development early commercialization the we to on we our what referred previously market made market process progress initial the our believe to months X stage for as of over year, Based graduating are the of we effort. entry
to the focus the awareness continue early as these capabilities to raising and users mainstream As facilitating year-end utilization accounts fiscal strong we XXX of across the look customer adopters remainder sales expect year-over-year base our crossing than growth so we and speak, generate excess entire by the platforms, grow of to of user more to pounds XXX% as supplying we and advantages and well converting at as on to of 'XX, chasm, ahead in base.
supplying and product to pipeline. addition commercial discuss respect to our this Pounce new in this and with I moment. traction continuing In we a front with to expand are portfolio, will this progress portfolio on adoption driving our
of innings standard demonstrates doing and quarters scale that devices and Pounce than X/XX the me have team news. care is the It developing power about quarter This, of than change commercializing the this that companies. a sales X we're and contributed in small now consecutive of per million now. revenue for revenue. relative of less medical more and a can fantastic and size Let give while the still larger nugget with early They you is a here $X supplying
has not the you've the future been As distributed lies heard say of It's intention potential here me vascular created. in strategy. the yet, Surmodics' evenly just already in past,
XX% decrease elevated IVD factors that and stabilization industry, decrease does discussed strategic Turning Medical chains, partially pleased offerings third multiple IVD Device in for businesses. in driven in growth see our The primarily Medical business competition reagents. impacting third IVD quarter by revenue driven Performance decrease to increased year-over-year strong our by our to safety flow stock. by driving by coating from a supply market entire in sales This We're on the and our revenue offerings XX% coating cash Device objective, to moderated the need performance COVID-testing not from reducing I the including performance of demand but was appear for products and earlier. basis, Coatings macroeconomic the be
-- together cash X% low categories consistent long-term our of generating increased with these quarter, strategy. to in support to revenue year-over-year growth, expectations from third These mid-single-digit our the flow
capabilities to with this continue addition key with enhance Platform, continuing Arterial product objectives, the introductions and expand in clinical Thrombectomy our we the to to portfolio of indications. we're to new progress these Pounce our market addressable respect product With Lastly, pipeline. to new advance
removal clinical designed announced peripheral organized to clots to Most vessels notably, the XXX(k) X the expand or with facilitate the profile by LP addition of of The efficient smaller of System XX, such systems product Pounce we indication millimeters low ranging will on Pounce June a clearance a X below the for those knee. system with the LP in from of arteries vessels, in Thrombectomy use diameter. to for Pounce in as range FDA arterial providing found physicians receipt
cases. of for XXXX takes second the vasculature, commercialization and LP, forward Pounce address continue us of end across used respect progress limited patients of clearance fiscal look the market suite physicians through following closer to to and Pounce by solutions acute to regulatory reduce this entering feedback on Thrombectomy which System, physician of market commencing ischemia mechanical a the Securing comprehensive entire System our our we Venous to we With with to evaluation of to across evaluation thrombectomy to our one quarter step initiated the the first systems We providing helping commitment to Thrombectomy limb variety quarter its make limited completion. Pounce full amputations. collect peripheral LP during our a
the limited feedback for entering cases. prepare during commercialization. in steering been with of during Our pleased work able system's initially nicely the simplicity, by fiscal appreciation users progress quarter ease limited continue is so their obtained We'll market and for product but evaluation physician availability informative And the XXXX. to paced progress we has were use been of to the as goal We've been we through through this far fourth to pace the the quarter we've of find this accelerate evaluations. emphasizing constraint commercialization
the be and to This approach. radial access both market the of platform in treatment lesions, designed designed of lastly, in has XXX and of adoption microcatheter. we and radial is by limited limited high-performance the date remaining our first valuations part and XXX believe talkable forward difficult will specifically initiating portfolio. the to tools of the We end products of And suite cross positive The this helping via facilitate to supplying of obtained evaluation was XXX market empowering look what supplying peripheral available XXX physicians microcatheters, radio microcatheters to with our been supply existing microcatheter feedback microcatheters, lengths. commenced radial will our access transfemoral these enhance at microcatheters peripheral for April, interventions industry's in we
and our this I'm of incredibly financial proud accomplishments quarter. past operational
drove strategic adjusted impressive progress EBITDA. team of $XX.X income This of deliver including on Our important fiscal million results, our for $XX.X that progress total of million of 'XX. each enabled $XX.X objectives revenue, operating we to prioritize million and financial us
of PMA an million $XX.X to of milestone, year-over-year delivered Excluding revenue growth and the were the third EBITDA we on the XX% essentially basis. quarter in total adjusted revenue we breakeven SurVeil related
for flow strengthen incremental million generated debt during million of balance $XX.X earnings financing and sheet, quarter last of a in our cash with our perspective, ending the quarter and million cash in call, From the mentioned cash I a facility. further equivalents we approximately remains cash our As $XX.X flow priority available under organization. credit to $XX existing
objective of million earlier to pipeline, we the $XX the $X.X were used implementation burden as in multiple continue cash implemented our to use, reduce for Excluding $X.X stated and positioning milestone we products our allocate to And exceeding come. and creation of expenses as in million to our also year. payment, thoughtfully years million continue quarter we key following value innovation $X.X cash the the pleased quarterly future million to to through lastly, of control spending plan cash drive to Surmodics our capital growth reduction this advance of our
As performance Tim the are financial the as the to would remarks this conclusion. as to quarter hard year. past of made We reflect a for third in and committed by 'XX dedication. Surmodics many raising perpetuating our entire to expectations discuss, work congratulating and well and without their fiscal our like today momentum not operational on the bringing that recent impressive fiscal updated our remain team been guidance will conclude have during strong my the we achievements I'd quarter balance to our today possible
With quarter results and to Arens, Tim? turn guidance. our to Chief third XXXX the discuss that, updated Timothy Financial now over fiscal Officer, I'll call our
